Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Morphine Clear all
Completed Phase 1Phase 2 Interventional Results available

Measuring the Amount of Methadone or Morphine in the Blood of Neonates, Infants & Children After Cardiac Surgery.

NCT01094522
View directory record Official record
Conditions
Pain
Interventions
Methadone, Morphine
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 5 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Stanford, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions

NCT00759356
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate sustained-release capsules, KADIAN
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 15, 2026, 2:37 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Obexelimab, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

NCT04298853
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine PRN, Morphine scheduled
Drug
Lead sponsor
Indiana University
Other
Eligibility
Up to 28 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome

NCT02851303
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Morphine, Methadone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
0 Hours to 12 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 15, 2026, 2:37 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586023
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
12
States / cities
Cullman, Alabama • Phoenix, Arizona • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

NCT04470050
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Lakes, Florida • Marlton, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

NCT04410991
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
43
States / cities
Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Masked Faces in Parkinson Disease: Mechanism and Treatment

NCT00350402
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Respiratory muscle strength training
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 15, 2026, 2:37 PM EDT
Withdrawn Phase 3 Interventional

Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)

NCT04455802
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Buprenorphine or Placebo, Morphine or Placebo
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery

NCT00390039
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intranasal morphine, Placebo, IV morphine
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
7
States / cities
Phoenix, Arizona • Bakersfield, California • State College, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2008 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

NCT01036165
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RebiSmart™
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

NCT00831051
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003, Morphine sulfate, Oxycodone HCl, Oxycodone HCl 4mg
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Anaheim, California • Owings Mills, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents

NCT00330343
View directory record Official record
Conditions
Pain, Nausea, Pruritus
Interventions
naloxone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults

NCT01869374
View directory record Official record
Conditions
Depression, Major Depressive Episode, Bipolar Disorder
Interventions
MagVenture MagPro MST, RUL ECT
Device · Biological
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants

NCT07130097
View directory record Official record
Conditions
Healthy Participant
Interventions
PF-07220060
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Epidural Morphine Versus Epidural Fentanyl Infusion Following Cesarean Section

NCT01362998
View directory record Official record
Conditions
Pain
Interventions
Preservative free morphine, Fentanyl
Drug
Lead sponsor
Goodman, Evan, M.D.
Individual
Eligibility
18 Years to 50 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 15, 2026, 2:37 PM EDT
Withdrawn Phase 4 Interventional

Assessment of Opioid Analgesia in Sickle Cell

NCT00513864
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dextromethorphan, Codeine, Morphine
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
7 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

NCT00640042
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate extended release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
378
States / cities
Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 15, 2026, 2:37 PM EDT
Completed No phase listed Observational

Vancomycin Associated Red Man Syndrome (RMS)

NCT00824122
View directory record Official record
Conditions
Red Man Syndrome
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Months to 21 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Intraosseous Morphine in Primary TKA

NCT04388111
View directory record Official record
Conditions
Knee Disease, Arthritis Knee, Pain, Acute
Interventions
Morphine
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 15, 2026, 2:37 PM EDT